Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclomethyltryptophan SCHEMBL416557 | 1.00 | KDM4E (0.71) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 | |
| Cyclomethyltryptophan SCHEMBL416558 | 1.00 | KDM4E (0.71) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 | |
| Cyclomethyltryptophan SCHEMBL29535380 | 1.00 | KDM4E (0.71) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 | |
| Cyclomethyltryptophan SCHEMBL10642614 | 0.98 | KDM4E (0.69) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 | |
| Cyclomethyltryptophan SCHEMBL28419799 | 0.98 | KDM4E (0.69) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12257169 | 0.90 | CYP2D6 (0.58) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10639172 | 0.87 | KDM4E (0.69) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1877421 | 0.87 | KDM4E (0.69) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3110230 | 0.87 | KDM4E (0.73) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13840607 | 0.87 | KDM4E (0.73) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4627079-A2 | THERMOSTABLE BINDING SCAFFOLDS | Nectagen, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20250222146-A1 | Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof | RAYZEBIO, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| WO-2025137441-A1 | RADIOPHARMACEUTICALS TARGETING SOMATOSTATIN RECEPTOR 2 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025137443-A1 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING SOMATOSTATIN RECEPTORS AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-4551563-A2 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119816487-A | FC conjugates comprising CD73 inhibitors and uses thereof | 奇达拉治疗公司 | 2025-04-11 | — | — | CN | disclosed |
| WO-2025064788-A2 | CCR5 CONJUGATES AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| CN-114980933-B | Compositions and methods for treating viral infections | 奇达拉治疗公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-119053336-A | Compositions and methods for treating autoimmune disorders | 密执安大学评议会 | 2024-11-29 | — | — | CN | disclosed |
| CN-118879592-A | Unnatural base pair compositions and methods of use | 斯克利普斯研究所 | 2024-11-01 | — | — | CN | disclosed |
| WO-2006117548-A1 | HYDROXAMIC ACID DERVICATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006117549-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
| US-5866587-A | HYDROXAMIDE DERIVATIVES OF FUSED PIPERIDINE DERIVATIVES | ADIR ET COMPAGNIE (FR) | 1999-02-02 | — | — | US | disclosed |
| EP-0491943-A4 | TETRAHYDROPYRIDOINDOLES AS CHOLECYSTOKININ AND GASTRIN ANTAGONISTS | RORER INT HOLDINGS (US) | 1996-02-14 | — | — | EP | disclosed |
| US-5162336-A | Disorders of gastrointestinal, central nervous and appetite regulatory systems | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1992-11-10 | — | — | US | disclosed |
| EP-0491943-A1 | TETRAHYDROPYRIDOINDOLES AS CHOLECYSTOKININ AND GASTRIN ANTAGONISTS | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-07-01 | — | — | EP | disclosed |
| WO-1992000295-A1 | TETRAHYDROPYRIDOINDOLES AS CHOLECYSTOKININ AND GASTRIN ANTAGONISTS | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-01-09 | — | — | WO | disclosed |
| EP-0145304-B1 | TETRAHYDRO-BETA-CARBOLINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Tanabe Seiyaku Co., Ltd. (JP) | 1988-04-20 | — | — | EP | disclosed |
| US-4628057-A | Tetrahydro-β-carboline derivatives and treatment of liver diseases | TANABE SEIYAKU CO., LTD. (JP) | 1986-12-09 | — | — | US | disclosed |
| EP-0145304-A1 | Tetrahydro-beta-carboline derivatives and process for the preparation thereof | Tanabe Seiyaku Co., Ltd. (JP) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250222146-A1 | Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof | SSTR2, SSTR4, SSTR5 | KDM4E 3869/4885CYP2D6 3307/4885CYP1A2 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.